524606 BERLDRG

Beryl Drugs Share Price

₹37.50 +0.25 (0.67%)

29 Dec, 2024 09:03

SIP TrendupStart SIP in BERLDRG

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month + 10.39%
  • Over 3 Month -0.95%
  • Over 6 Month + 17.22%
  • Over 1 Year + 66.37%
SIP Lightning

Smart Investing Starts Here Start SIP with Beryl Drugs for Steady Growth!

Invest Now

Beryl Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Beryl Drugs Financials

Beryl Drugs Technicals

EMA & SMA

Current Price
₹37.50
+ 0.25 (0.67%)
pointer
  • stock-down_img
  • Bullish Moving Average 15
  • stock-up_img
  • Bearish Moving Average 1
  • 20 Day
  • ₹36.72
  • 50 Day
  • ₹36.32
  • 100 Day
  • ₹35.74
  • 200 Day
  • ₹33.77

Resistance and Support

36.61 Pivot Speed
  • R3 40.11
  • R2 38.87
  • R1 37.85
  • S1 35.59
  • S2 34.35
  • S3 33.33

What's your outlook on Beryl Drugs?

You can only vote for once

Beryl Drugs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results
2024-08-09 Quarterly Results
2024-05-30 Audited Results
2024-04-20 Others
2024-02-12 Quarterly Results

Beryl Drugs F&O

Beryl Drugs Shareholding Pattern

No data available.

About Beryl Drugs

  • NSE Symbol
  • BERLDRG
  • BSE Symbol
  • 524606
  • ISIN
  • INE415H01017

Similar Stocks to Beryl Drugs

Beryl Drugs FAQs

Beryl Drugs share price is ₹37 As on 29 December, 2024 | 08:49

The Market Cap of Beryl Drugs is ₹19 Cr As on 29 December, 2024 | 08:49

The P/E ratio of Beryl Drugs is 56.1 As on 29 December, 2024 | 08:49

The PB ratio of Beryl Drugs is 2.1 As on 29 December, 2024 | 08:49

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23